Monthly ReportJul 1–31, 2026
Anesthesiology, July 2026 edition
We read 2881 papers and selected 5.
Summary
July 2026 anesthesiology research emphasized individualized organ protection, precision risk stratification, and recovery-oriented care. The strongest clinical signals were perioperative dapagliflozin for prevention of cardiac-surgery-associated acute kidney injury, higher intraoperative MAP targets for selected hypertensive patients, and inflammatory phenotype-guided treatment strategies in severe pneumonia. Translational research expanded mechanistic understanding of thrombosis, intracranial pressure, chronic pain, and perioperative neurocognitive disorders through adipose, lymphatic, immune, and cellular pathways. Across the month, randomized trials increasingly challenged routine practices and supported procedure-, phenotype-, and patient-specific treatment selection.
Selected Articles
1. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
In a multicenter, double-blind randomized trial of 784 adults undergoing elective cardiac surgery, four perioperative doses of dapagliflozin initiated one day before surgery reduced acute kidney injury at seven days from 52% to 28% compared with placebo. The relative risk was 0.54, with nearly complete follow-up and similar rates of atrial fibrillation and reoperation between groups.
Impact: This large, high-quality randomized trial addresses a common and serious postoperative complication for which effective pharmacologic prevention has been limited. The magnitude of benefit could substantially influence renal-protection protocols in cardiac surgery.
Clinical Implications: Perioperative dapagliflozin is a promising candidate for prevention of acute kidney injury after elective cardiac surgery, but routine adoption should await replication and careful assessment of volume status, renal function, diabetes, and SGLT2 inhibitor-related safety risks.
Key Findings
- Acute kidney injury occurred in 28% with dapagliflozin versus 52% with placebo.
- The relative risk of acute kidney injury was 0.54, with a 95% confidence interval of 0.45 to 0.65.
- Atrial fibrillation and reoperation rates were similar between groups.
2. Cold exposure aggravates vein occlusion through non-shivering thermogenesis-induced thrombocytopoiesis.
This translational study showed that cold exposure increased platelet production through adipose thermogenesis and circulating free fatty acids. Fatty-acid beta-oxidation promoted megakaryocyte maturation through an acetyl-CoA–C/EBPα pathway, while pathway inhibition reduced venous thrombosis in mice. Human observations showed higher platelet counts during cold exposure and cold seasons.
Impact: The study offers a novel environmental-metabolic explanation for seasonal thrombotic risk and connects temperature, adipose thermogenesis, platelet production, and venous occlusion across mechanistic and human observations.
Clinical Implications: Cold exposure may represent a modifiable risk factor for venous thrombosis in susceptible patients, but the findings remain primarily translational and do not yet justify a specific clinical intervention.
Key Findings
- Cold exposure increased platelet counts and aggravated deep venous thrombosis and retinal vein occlusion in mice.
- Adipose thermogenesis and fatty-acid beta-oxidation promoted acetyl-CoA-dependent platelet production.
- Pathway inhibition reduced cold-induced thrombocytopoiesis and venous occlusion.
3. Inflammatory Phenotypes In Severe Pneumonia: Clinical Evidence To Mouse Models For Precision Therapeutics.
Latent class analysis identified hyperinflammatory and hypoinflammatory phenotypes among 548 critically ill patients with pulmonary sepsis. The hyperinflammatory phenotype was associated with greater lung injury and mortality. In a pneumococcal pneumonia mouse model, dexamethasone and IL-6 receptor blockade benefited only the more inflamed phenotype.
Impact: This study directly links clinically observed inflammatory subgroups to reproducible experimental biology and differential treatment responses, providing a strong framework for precision immunomodulation in severe pneumonia and sepsis.
Clinical Implications: Biomarker-based inflammatory phenotyping may eventually guide corticosteroid or IL-6 pathway therapy, but prospective biomarker-stratified clinical trials are required before implementation.
Key Findings
- Two inflammatory phenotypes were identified among 548 patients with pulmonary sepsis.
- The hyperinflammatory phenotype was associated with greater lung injury and mortality.
- Dexamethasone and IL-6 receptor blockade benefited only the more inflamed experimental phenotype.
4. Cerebral venous blood flow regulates intracerebral pressure and brain clearance via meningeal lymphatic vessels.
This translational study integrated MRI findings from patients with idiopathic intracranial hypertension with mechanistic mouse experiments. Dural venous sinus stenosis was associated with altered perivenous fluid patterns and brain edema, while jugular vein ligation caused transient intracerebral hypertension and impaired clearance. Depletion of meningeal lymphatic vessels worsened pressure elevation and prevented recovery of brain-fluid clearance.
Impact: The study reframes intracranial pressure regulation by establishing a functional connection between cerebral venous outflow, meningeal lymphatics, edema, and brain-fluid clearance.
Clinical Implications: Neuroanesthesia and neurocritical care may need to consider venous outflow and meningeal lymphatic integrity as components of intracranial pressure physiology. However, the findings do not yet establish a new clinical treatment standard.
Key Findings
- Dural venous sinus stenosis was associated with altered perivenous fluid patterns and brain edema in idiopathic intracranial hypertension.
- Jugular vein ligation caused transient intracerebral hypertension, edema, and impaired brain-fluid clearance in mice.
- Meningeal lymphatic depletion worsened pressure elevation and prevented clearance recovery.
5. Effectiveness of transcutaneous auricular vagus nerve stimulation in alleviating postpartum blues following cesarean delivery: A randomized double-blind controlled trial.
In a double-blind randomized trial of 100 patients after cesarean delivery, five days of transcutaneous auricular vagus nerve stimulation reduced postpartum blues severity, improved mood, lowered the proportion with Edinburgh Postnatal Depression Scale scores of 13 or higher at one month, reduced acute postoperative pain, and improved sleep quality. Effects were observed across multiple patient-reported outcomes with follow-up to three months.
Impact: This blinded randomized trial identified a feasible, nonpharmacologic intervention that simultaneously addressed postpartum mood, pain, and sleep, all of which are relevant to obstetric anesthesia and enhanced recovery.
Clinical Implications: Transcutaneous auricular vagus nerve stimulation could be considered as an adjunct in post-cesarean recovery pathways for selected patients, but larger multicenter studies are needed before routine implementation.
Key Findings
- Postpartum blues severity was significantly lower after five days of active stimulation than after sham stimulation.
- The proportion with Edinburgh Postnatal Depression Scale scores of 13 or higher at one month was 4% with stimulation versus 26% with sham.
- Pain decreased from 4 to 72 hours and sleep quality improved during postoperative days 1 to 4.